What are examples of prokinetic medications for gastroparesis?

Prokinetic Medications for Gastroparesis

The primary prokinetic agents for gastroparesis are metoclopramide and erythromycin, with metoclopramide being the only FDA-approved medication for this indication. 1

First-Line Prokinetic Agents

Metoclopramide (Preferred First-Line)

Metoclopramide is the AGA's suggested first-line prokinetic agent (conditional recommendation, low-quality evidence). 1 This dopamine D2 antagonist is the only FDA-approved medication specifically for gastroparesis treatment.

Dosing:

• Start with 5 mg orally before meals (three times daily)
• Can titrate up to 10 mg before meals based on response
• Intranasal formulation: 15 mg before meals and at bedtime 1

Critical Safety Considerations:

• FDA black box warning for tardive dyskinesia risk
• Higher risk in older patients and those on psychotropic agents, though absolute risk remains low
• Assess efficacy and adverse effects at 4-8 weeks
• Consider drug holidays (1-4 weeks off every 8-12 weeks) to improve tolerability 1

Erythromycin (Alternative First-Line)

The AGA suggests erythromycin as an alternative first-line prokinetic (conditional recommendation, very low-quality evidence). 1 This macrolide antibiotic works through motilin receptor agonism, unrelated to its antimicrobial properties.

Dosing:

• Low doses: 40-150 mg orally 30 minutes before meals
• Use erythromycin ethylsuccinate oral suspension to allow smaller, better-tolerated doses (tablets only available in 250-500 mg) 1

Critical Limitations:

• Tachyphylaxis develops with continuous use
• Maintain efficacy using drug holidays (e.g., 3 weeks on, 1 week off)
• Safety concerns: antibiotic resistance, CYP3A inhibitor interactions, QT prolongation 1

Second-Line and Alternative Prokinetic Agents

Domperidone (NOT First-Line)

The AGA suggests AGAINST domperidone as first-line treatment (conditional recommendation, very low-quality evidence). 1 However, it may be considered for patients who:

• Experienced neurologic adverse effects with metoclopramide
• Have Parkinson's disease or other movement disorders
• Decline metoclopramide due to safety concerns 1

Critical Access Issue:

• NOT FDA-approved in the United States
• Requires expanded access IND application
• Current supplier exiting the market (as of guideline publication) 1

If Available:

• Requires baseline ECG, potassium, and magnesium monitoring
• Ongoing QTc interval monitoring during treatment 1

Prucalopride (NOT First-Line)

The AGA suggests AGAINST prucalopride as first-line treatment (conditional recommendation, very low-quality evidence). 1 This 5-HT4 receptor agonist has purely prokinetic effects without direct antiemetic properties.

May Consider For:

• Patients with idiopathic gastroparesis (more responsive than diabetic or connective tissue disease-related)
• Patients with concurrent chronic idiopathic constipation (dual indication efficiency) 1

Safety Note:

• Monitor for depression and suicidal ideation risk 1

Non-Prokinetic Agents Sometimes Confused as Prokinetics

Aprepitant

• Neurokinin-1 receptor antagonist
• NO effect on gastric motor function
• Purely antiemetic for refractory nausea/vomiting when 5-HT3 antagonists fail 1

Nortriptyline and Buspirone

• NOT prokinetics
• Nortriptyline: peripheral neuromodulator for pain, early satiety, fullness 1
• Buspirone: fundic relaxant for early satiety and bloating 1

Clinical Algorithm for Prokinetic Selection

Step 1: Start with metoclopramide OR erythromycin 1

• Choose metoclopramide if: Standard gastroparesis presentation, no movement disorder history
• Choose erythromycin if: Concern for neurologic side effects, need to avoid dopamine antagonism

Step 2: Assess at 4-8 weeks 1

• Continue if effective and tolerated
• Adjust dose or switch if partial response
• Discontinue if ineffective or intolerable side effects

Step 3: If first-line fails, consider:

• Switching between metoclopramide and erythromycin
• Adding domperidone (if accessible and appropriate monitoring available)
• Prucalopride for idiopathic gastroparesis with constipation 1

Common Pitfalls to Avoid

1. Do not use prokinetics during gastric emptying studies - they confound results 1
2. Do not forget drug holidays - prevents tachyphylaxis with erythromycin and may improve metoclopramide tolerability 1
3. Do not use azithromycin as equivalent substitute - similar antibiotic resistance concerns apply 1
4. Do not overlook QT prolongation risk - both erythromycin and domperidone require cardiac monitoring 1
5. Do not expect antiemetics to improve motility - ondansetron, promethazine, and prochlorperazine reduce symptoms without affecting gastric emptying 1